# Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma

> **NCT03035188** · PHASE2 · COMPLETED · sponsor: **SRH Wald-Klinikum Gera GmbH** · enrollment: 40 (actual)

## Conditions studied

- Basal Cell Carcinoma

## Interventions

- **DRUG:** Vismodegib

## Key facts

- **NCT ID:** NCT03035188
- **Lead sponsor:** SRH Wald-Klinikum Gera GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2020-01
- **Final completion:** 2021-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03035188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03035188, "Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03035188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*